200,000+ products from a single source!
sales@angenechem.com
209783-80-2 | Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester
CAS No: 209783-80-2 Catalog No: AG002KDZ MDL No:MFCD03453552
Product Description
Catalog Number:
AG002KDZ
Chemical Name:
Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester
CAS Number:
209783-80-2
Molecular Formula:
C21H20N4O3
Molecular Weight:
376.4085
MDL Number:
MFCD03453552
IUPAC Name:
pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
InChI:
InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)
InChI Key:
INVTYAOGFAGBOE-UHFFFAOYSA-N
SMILES:
O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N
UNII:
1ZNY4FKK9H
NSC Number:
706995
Properties
Complexity:
508
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
376.154g/mol
Formal Charge:
0
Heavy Atom Count:
28
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
376.416g/mol
Monoisotopic Mass:
376.154g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
106A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2
Literature
| Title | Journal |
|---|---|
| The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. | Archives of toxicology 20180701 |
| A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. | Nature genetics 20180701 |
| Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay. | Archives of toxicology 20170101 |
| Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Tox(ukn) and STOP-Tox(ukk) tests. | Archives of toxicology 20170101 |
| Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. | Leukemia research 20160601 |
| Epigenetic Modulators and the New Immunotherapies. | The New England journal of medicine 20160218 |
| The Effects of Class-Specific Histone Deacetylase Inhibitors on the Development of Limbs During Organogenesis. | Toxicological sciences : an official journal of the Society of Toxicology 20151101 |
| Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function. | Nucleic acids research 20150420 |
| Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. | Chemistry & biology 20150219 |
| A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. | Archives of toxicology 20150101 |
| Histone deacetylase 4 promotes ubiquitin-dependent proteasomal degradation of Sp3 in SH-SY5Y cells treated with di(2-ethylhexyl)phthalate (DEHP), determining neuronal death. | Toxicology and applied pharmacology 20141001 |
| Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. | PloS one 20140101 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position. | Bioorganic & medicinal chemistry letters 20121201 |
| A combined approach for the study of histone deacetylase inhibitors. | Molecular bioSystems 20121101 |
| Histone deacetylase inhibitors preserve function in aging axons. | Journal of neurochemistry 20121101 |
| Novel agents in Hodgkin lymphoma. | Current oncology reports 20121001 |
| P300/CBP associated factor regulates nitroglycerin-dependent arterial relaxation by N(ε)-lysine acetylation of contractile proteins. | Arteriosclerosis, thrombosis, and vascular biology 20121001 |
| MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice. | European journal of pharmacology 20120915 |
| Effect of valproic acid on mitochondrial epigenetics. | European journal of pharmacology 20120905 |
| HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. | Nature neuroscience 20120901 |
| Histone deacetylase inhibitors: structure-based modeling and isoform-selectivity prediction. | Journal of chemical information and modeling 20120827 |
| P38 MAP kinase functions as a switch in MS-275-induced reactive oxygen species-dependent autophagy and apoptosis in human colon cancer cells. | Free radical biology & medicine 20120801 |
| Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity. | Bioorganic & medicinal chemistry 20120715 |
| Increased neuron specific enolase expression by urothelial cells exposed to or malignantly transformed by exposure to Cd²⁺ or As³⁺. | Toxicology letters 20120707 |
| Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3. | Journal of cellular and molecular medicine 20120701 |
| Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors. | European journal of medicinal chemistry 20120701 |
| Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. | The Journal of clinical endocrinology and metabolism 20120701 |
| Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. | Chemistry & biology 20120622 |
| Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120620 |
| Antitumor activity of Chidamide in hepatocellular carcinoma cell lines. | Molecular medicine reports 20120601 |
| HDAC1 regulates fear extinction in mice. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20120411 |
| Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex. | Brain research 20120404 |
| Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. | Circulation research 20120302 |
| Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain. | Bioorganic & medicinal chemistry letters 20120301 |
| [Histone deacetylase inhibitor MS-275 treatment alters immune molecule content and categories in hepatocarcinoma exosomes]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20120301 |
| Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. | Blood 20120202 |
| Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. | Investigational new drugs 20120201 |
| Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. | Neuro-oncology 20120201 |
| Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. | British journal of cancer 20120103 |
| HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis. | The Prostate 20120101 |
| Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-γ. | PLoS pathogens 20120101 |
| Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. | PloS one 20120101 |
| Loss of deacetylation activity of Hdac6 affects emotional behavior in mice. | PloS one 20120101 |
| Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation. | Scientific reports 20120101 |
| Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. | PloS one 20120101 |
| Novel therapies for aggressive B-cell lymphoma. | Advances in hematology 20120101 |
| Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. | OncoTargets and therapy 20120101 |
| A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier. | ChemMedChem 20111209 |
| Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. | Journal of cellular physiology 20111201 |
| Histone deacetylase inhibitors and periodontal bone loss. | Journal of periodontal research 20111201 |
| Raman microspectroscopy detects epigenetic modifications in living Jurkat leukemic cells. | Epigenomics 20111201 |
| Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. | Cancer discovery 20111201 |
| The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. | Bioorganic & medicinal chemistry letters 20111015 |
| The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. | Experimental hematology 20111001 |
| Entinostat for treatment of solid tumors and hematologic malignancies. | Expert opinion on investigational drugs 20111001 |
| Histone deacetylase inhibitor MS-275 stimulates bone formation in part by enhancing Dhx36-mediated TNAP transcription. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110901 |
| Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. | Cancer chemotherapy and pharmacology 20110901 |
| Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells. | The Journal of biological chemistry 20110826 |
| Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma. | World journal of gastroenterology 20110821 |
| Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20110815 |
| Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. | Cancer 20110801 |
| HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. | Cancer letters 20110801 |
| Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition. | Brain : a journal of neurology 20110801 |
| A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. | Bioorganic & medicinal chemistry letters 20110715 |
| Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. | Journal of medicinal chemistry 20110714 |
| The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. | Oncogene 20110707 |
| Aromatase inhibitors and xenograft studies. | Steroids 20110701 |
| Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells. | Leukemia research 20110701 |
| Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. | Anti-cancer drugs 20110701 |
| Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. | Bioorganic & medicinal chemistry 20110615 |
| Analysis of the GAD1 promoter: trans-acting factors and DNA methylation converge on the 5' untranslated region. | Neuropharmacology 20110601 |
| Histone deacetylase inhibition alters histone methylation associated with heat shock protein 70 promoter modifications in astrocytes and neurons. | Neuropharmacology 20110601 |
| Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory. | Learning & memory (Cold Spring Harbor, N.Y.) 20110601 |
| Clinical development of panobinostat in classical Hodgkin's lymphoma. | Expert review of hematology 20110601 |
| HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110515 |
| Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. | Neuroscience letters 20110415 |
| Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. | Cancer research 20110301 |
| [Design, synthesis, and biological activities of histone deacetylase inhibitors with diketo ester as zinc binding group]. | Yao xue xue bao = Acta pharmaceutica Sinica 20110301 |
| Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis. | The Journal of biological chemistry 20110211 |
| DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome. | Journal of Korean medical science 20110201 |
| Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. | Cancer research 20110115 |
| Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. | Molecular pharmacology 20110101 |
| Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy. | Bioorganic & medicinal chemistry letters 20110101 |
| Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. | Journal of biomedicine & biotechnology 20110101 |
| Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? | Journal of biomedicine & biotechnology 20110101 |
| Differences in the epigenetic regulation of MT-3 gene expression between parental and Cd+2 or As+3 transformed human urothelial cells. | Cancer cell international 20110101 |
| Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth. | Molecular cancer 20110101 |
| Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. | BMC medicine 20110101 |
| Interpreting clinical assays for histone deacetylase inhibitors. | Cancer management and research 20110101 |
| Myelodysplastic syndrome and histone deacetylase inhibitors: 'to be or not to be acetylated'? | Journal of biomedicine & biotechnology 20110101 |
| Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. | Journal of biomedicine & biotechnology 20110101 |
| Epigenetics in breast cancer: what's new? | Breast cancer research : BCR 20110101 |
| Epigenetics in prostate cancer. | Prostate cancer 20110101 |
| Romidepsin in the treatment of cutaneous T-cell lymphoma. | Journal of blood medicine 20110101 |
| Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. | European journal of nuclear medicine and molecular imaging 20101201 |
| Inhibitors selective for HDAC6 in enzymes and cells. | Bioorganic & medicinal chemistry letters 20101201 |
| MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. | Molecular cancer therapeutics 20101201 |
| The DAC system and associations with multiple myeloma. | Investigational new drugs 20101201 |
| Histone deacetylase inhibitors in Hodgkin lymphoma. | Investigational new drugs 20101201 |
| Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. | Investigational new drugs 20101201 |
| Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. | Journal of cellular physiology 20101101 |
| Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. | Autophagy 20101101 |
| Histone deacetylase inhibitors in the treatment of lymphoma. | Discovery medicine 20101101 |
| Absence of Metallothionein 3 Expression in Breast Cancer is a Rare, But Favorable Marker of Outcome that is Under Epigenetic Control. | Toxicological and environmental chemistry 20101001 |
| Histone deacetylase inhibitors in lymphoma. | Current opinion in oncology 20100901 |
| MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. | Neuroscience 20100811 |
| Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. | Rheumatology (Oxford, England) 20100801 |
| American Society of Clinical Oncology--46th annual meeting. | IDrugs : the investigational drugs journal 20100801 |
| Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. | Journal of medicinal chemistry 20100624 |
| New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group. | Bioorganic & medicinal chemistry 20100601 |
| Epigenetic therapy of lymphoma using histone deacetylase inhibitors. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100601 |
| [Histone acetylation, gene regulation and depression]. | Medecine sciences : M/S 20100501 |
| Chemical phylogenetics of histone deacetylases. | Nature chemical biology 20100301 |
| MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. | European journal of pharmacology 20100210 |
| Induction of TAp63 by histone deacetylase inhibitors. | Biochemical and biophysical research communications 20100122 |
| Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. | Oncogene 20100107 |
| Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. | Urologic oncology 20100101 |
| HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity. | Oncology reports 20100101 |
| Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. | Nature chemical biology 20100101 |
| Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils. | Journal of inflammation (London, England) 20100101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. | PloS one 20100101 |
| An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. | OncoTargets and therapy 20100101 |
| Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine. | OncoTargets and therapy 20100101 |
| Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. | PloS one 20100101 |
| New treatments for myelodysplastic syndromes. | Mediterranean journal of hematology and infectious diseases 20100101 |
| Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201 |
| Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. | Molecular pharmacology 20091101 |
| HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. | Cancer research 20091101 |
| MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. | Blood 20091015 |
| Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. | International journal of oncology 20091001 |
| Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. | Blood 20090924 |
| HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines. | Biochemical and biophysical research communications 20090918 |
| Antidepressant actions of histone deacetylase inhibitors. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20090916 |
| Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. | Oncogene 20090903 |
| Epigenetic influences on sensory regeneration: histone deacetylases regulate supporting cell proliferation in the avian utricle. | Journal of the Association for Research in Otolaryngology : JARO 20090901 |
| Lysine acetylation targets protein complexes and co-regulates major cellular functions. | Science (New York, N.Y.) 20090814 |
| Recent advances in the development of polyamine analogues as antitumor agents. | Journal of medicinal chemistry 20090813 |
| Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. | Journal of neuro-oncology 20090701 |
| DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. | Stem cells (Dayton, Ohio) 20090701 |
| Epigenetic modifiers: basic understanding and clinical development. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Clinical studies of histone deacetylase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. | Journal of medicinal chemistry 20090611 |
| Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. | Stem cells and development 20090501 |
| Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. | Molecular pharmacology 20090501 |
| Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. | Haematologica 20090501 |
| [MS-275, a histone deacetylase inhibitor, induces apoptosis and alters survivin gene expression in human myeloma cell line U266]. | Ai zheng = Aizheng = Chinese journal of cancer 20090501 |
| Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. | Journal of medicinal chemistry 20090423 |
| [Effects of histone deacetylase inhibitor MS-275 on expression of survivin and NF-kappaB in the human myeloma cell line U266 cells]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090401 |
| Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives. | Bioorganic & medicinal chemistry 20090315 |
| Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. | Biological & pharmaceutical bulletin 20090301 |
| N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). | Bioorganic & medicinal chemistry letters 20090215 |
| Histone acetylation resulting in resistance to methotrexate in choroid plexus cells. | Journal of neuro-oncology 20090201 |
| The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. | Molecular pharmacology 20090201 |
| Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090115 |
| Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. | Cellular immunology 20090101 |
| 'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. | Retrovirology 20090101 |
| Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. | PloS one 20090101 |
| Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. | International journal of cancer 20081215 |
| Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. | Leukemia 20081201 |
| The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. | Oncology reports 20081101 |
| MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. | Leukemia research 20080901 |
| Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation. | Analytical chemistry 20080815 |
| Sp1-mediated TRAIL induction in chemosensitization. | Cancer research 20080815 |
| Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. | Melanoma research 20080801 |
| A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080715 |
| Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. | Leukemia 20080701 |
| p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. | Oncogene 20080605 |
| Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. | Molecular cancer therapeutics 20080601 |
| Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080515 |
| Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. | Leukemia research 20080501 |
| Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. | Bioorganic & medicinal chemistry letters 20080415 |
| MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. | British journal of cancer 20080408 |
| Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. | Journal of molecular graphics & modelling 20080401 |
| Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. | Bioorganic & medicinal chemistry 20080315 |
| Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. | Bioorganic & medicinal chemistry letters 20080315 |
| Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death. | Leukemia 20080301 |
| Histone deacetylase inhibitors in lymphoma and solid malignancies. | Expert review of anticancer therapy 20080301 |
| Regulation of arginase-1 expression in macrophages by a protein kinase A type I and histone deacetylase dependent pathway. | Journal of cellular biochemistry 20080201 |
| Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. | Leukemia research 20080201 |
| Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. | The Biochemical journal 20080115 |
| Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. | Bioorganic & medicinal chemistry letters 20071115 |
| Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. | Journal of medicinal chemistry 20071115 |
| Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. | Journal of cancer research and clinical oncology 20071101 |
| Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. | The Journal of biological chemistry 20070928 |
| Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070915 |
| Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. | World journal of gastroenterology 20070907 |
| Trithiocarbonates: exploration of a new head group for HDAC inhibitors. | Bioorganic & medicinal chemistry letters 20070901 |
| Relationship between embryonic histonic hyperacetylation and axial skeletal defects in mouse exposed to the three HDAC inhibitors apicidin, MS-275, and sodium butyrate. | Toxicological sciences : an official journal of the Society of Toxicology 20070801 |
| Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. | The Prostate 20070801 |
| Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070801 |
| Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070701 |
| Bispyridinium dienes: histone deacetylase inhibitors with selective activities. | Journal of medicinal chemistry 20070517 |
| MAGE-A9 mRNA and protein expression in bladder cancer. | International journal of cancer 20070515 |
| Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. | Bioorganic & medicinal chemistry letters 20070415 |
| Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. | Blood 20070401 |
| Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. | British journal of pharmacology 20070401 |
| The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. | Cancer gene therapy 20070301 |
| A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. | Journal of pharmaceutical and biomedical analysis 20070117 |
| Measuring cytotoxicity: a new perspective on LC50. | Anticancer research 20070101 |
| MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. | The international journal of biochemistry & cell biology 20070101 |
| HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. | The international journal of biochemistry & cell biology 20070101 |
| Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. | Endocrine-related cancer 20061201 |
| Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. | Investigational new drugs 20060901 |
| Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20060801 |
| Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. | Acta neuropathologica 20060801 |
| Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. | Molecular cancer therapeutics 20060501 |
| Curcumin is an inhibitor of p300 histone acetylatransferase. | Medicinal chemistry (Shariqah (United Arab Emirates)) 20060301 |
| Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. | Cancer chemotherapy and pharmacology 20060201 |
| Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells. | Anticancer research 20060101 |
| Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. | Journal of molecular neuroscience : MN 20060101 |
| Histone deacetylase inhibitors in cancer therapy. | Cancer investigation 20060101 |
| Histone deacetylase inhibitors promote osteoblast maturation. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051201 |
| Targeting epigenetic changes in acute myeloid leukemia. | Clinical advances in hematology & oncology : H&O 20051101 |
| Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer. | Clinical prostate cancer 20050901 |
| Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. | Molecular and cellular biology 20050701 |
| [A new target of cancer therapy: advances in the study of histone deacetylase]. | Yao xue xue bao = Acta pharmaceutica Sinica 20050701 |
| In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. | The Prostate 20050615 |
| Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050610 |
| Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050501 |
| Histone deacetylase inhibitors and cancer: from cell biology to the clinic. | European journal of cell biology 20050301 |
| Peak shape improvement of basic analytes in capillary liquid chromatography. | Journal of separation science 20050201 |
| Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. | Annals of clinical and laboratory science 20050101 |
| Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040915 |
| Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. | Cancer biology & therapy 20040801 |
| The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. | Leukemia 20040701 |
| Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. | International journal of cancer 20040610 |
| Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040525 |
| The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. | Cancer research 20040401 |
| (2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20040105 |
| Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. | Cancer research 20040101 |
| Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. | Journal of medicinal chemistry 20031218 |
| Identification of novel isoform-selective inhibitors within class I histone deacetylases. | The Journal of pharmacology and experimental therapeutics 20031101 |
| Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. | Oncogene 20030918 |
| The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. | Cancer research 20030701 |
| Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. | Blood 20030301 |
| Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. | Molecular cancer therapeutics 20030201 |
| Trifluoromethyl ketones as inhibitors of histone deacetylase. | Bioorganic & medicinal chemistry letters 20021202 |
| MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. | Cancer research 20021101 |
| Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. | Cancer research 20020801 |
| Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. | Bioorganic & medicinal chemistry letters 20020520 |
| Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. | The Journal of biological chemistry 20020215 |
| MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. | Cancer research 20010201 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.